The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia

PESCHELOVÁ, Helena, Veronika KOZLOVÁ, Václav HEJRET and Michal ŠMÍDA. The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia. In Biomania, Brno. 2019.

Basic information

Original name

The use of CRISPR/Cas9 technology in the study of chronic lymphocytic leukemia

Authors

PESCHELOVÁ, Helena (203 Czech Republic, belonging to the institution), Veronika KOZLOVÁ (203 Czech Republic, belonging to the institution), Václav HEJRET (203 Czech Republic, belonging to the institution) and Michal ŠMÍDA (203 Czech Republic, guarantor, belonging to the institution)

Edition

Biomania, Brno, 2019

---

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30204 Oncology

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14740/19:00112810

Organization unit

Central European Institute of Technology

Keywords in English

CRISPR/Cas9; chronic lymphocytic leukemia

Tags

rivok

---

Abstract

V originále

CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia, CRISPR/Cas9-mediated gene knockout of TP53 and ATM in HG3 cell line: models for chronic lymphocytic leukemia.

---

Links

LQ1601, research and development project

Name: CEITEC 2020 (Acronym: CEITEC2020) Investor: Ministry of Education, Youth and Sports of the CR